Breast Cancer

Patients who experienced breakthrough CINV in their first chemotherapy cycle were more likely to have the adverse event in later cycles too, recent research found.

Patients from Asian countries with hormone receptor (HR)–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib (Verzenio).

The FDA granted an accelerated approval to pembrolizumab (Keytruda) plus chemotherapy for the treatment of patients with locally recurrent, unresectable or metastatic triple-negative breast cancer (TNBC) with PD-L1 expression is CPS ≥10, according to the agency.

A pharmacist provides an overview of new intravenous cancer therapies that were approved in 2020.

Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and eliciting impressive response rates in heavily pretreated patients.

Oncology nurses are key players in promoting health heart practices after a patient finishes cancer treatment.

While COVID-19 continues to present much uncertainty for many people, those diagnosed with breast cancer are faced with unique challenges in navigating continued treatment.

Recent years have brought many changes to the treatment of patients with HER2-positive metastatic breast cancer.

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Makers of breast implants should supplement their labeling to include a boxed warning about health problems that can arise from the devices, along with a patient decision checklist that highlights those concerns, according to final guidance issued today by the Food and Drug Administration.

It is crucial that oncology nurses have open lines of communications with their patients when it comes to adverse events.

Oncology nurses need to keep an eye out for diarrhea in their patients on CDK4/6 inhibitors.

The FDA has issued an alert to professionals, investigators, and patients that the phase 3 IMpassion131 trial (NCT03125902) failed to show the effectiveness of atezolizumab (Tecentriq) plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.

The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer.

Denise A. Yardley, MD, highlights the evolving role of adjuvant CDK4/6 inhibition in HR-positive metastatic breast cancer.

The Food and Drug Administration (FDA) provided an update on breast-implant associated side effects that have been reported to the agency, including breast implant-associated anaplastic large cell lymphoma (BI-ALCL) and symptoms that are commonly referred to by patients as breast implant illness (BII).

The HER2-positive breast cancer treatment paradigm is constantly changing, explained Debu Tripathy, MD, who cited that in less than 1 year, there have been 2 exciting drug approvals, which are tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu).

Patients with breast cancer may be apprehensive to come into the clinic for treatment amidst the coronavirus disease 2019 (COVID-19) pandemic. However, others may prefer seeing their treatment team in person.

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events (AEs) are properly managed—specifically in those patients with breast cancer, according to Patricia Jakel, RN, MN, AOCN.

Marking the first US applications for pembrolizumab in breast cancer, the applications are based on data from the KEYNOTE-355 and KEYNOTE-522 trials, respectively.

Heather Han, MD, discusses ongoing clinical trials within the field of HER2-positive breast cancer and the future of personalized treatment for this patient population.

Efbemalenograstim alpha (F-627) has demonstrated strong and lasting benefit when used as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, meeting the primary and secondary end points of a phase 3 study.

Patients with metastatic HER2-positive breast cancer who later develop central nervous system (CNS) metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup, explained Brian Czerniecki, MD, PhD.

The FDA approved subcutaneous Phesgo – a combination of pertuzumab (Perjeta), trastuzumab (Herceptin), and hyaluronidase–zzxf – for the treatment of patients with metastatic HER2-positive breast cancer, as well as early-stage HER2-positive breast cancer, as selected by an FDA-approved companion diagnostic test.